CytRx Corp. (CYTR) Gets Positive Review in Seeking Alpha’s E CytRx Corp. (CYTR) Gets Positive Review in Seeking Alpha’s Equity Stock Guru Article
Oncological biopharm company CytRx today was featured in a Seeking Alpha article detailing the company’s recent flurry of positive news as well as its promising drug candidate pipeline. Access the full article on Seeking Alpha here: https://seekingalpha.com/article/1797082.
As recapped in the article, CytRx’ lead candidate is aldoxorubicin, the company’s improve formulation of the commonly used chemotherapy agent doxorubicin. CytRx is currently pursuing several indications with aldoxorubicin:
• 2nd-Line Soft Tissue Sarcoma (STS)
• 1st-Line Soft Tissue Sarcoma
• Glioblastoma Multiforme (GBM)
• Kaposi’s Sarcoma
SeekingAlpha contributor Equity Options Guru also noted CytRx’ interim results from its phase 2b Trial for aldoxorubicin for 1st-Line Soft Tissue Sarcoma, which demonstrated that patients treated with the drug candidate had a higher overall response rate (22 percent) compared to those treated with doxorubicin (0 percent). The company is expected to release its top-line progression-free survival results in December 2013.
Among other points of interest, the article outlines four of CytRx’ upcoming events:
• 4th Quarter 2013 – CytRx plans to commence a phase 2 trial with aldoxorubicin in patients with relapsed glioblastoma.
• 4th Quarter 2013 – CytRx plans to begin a phase 2 trial evaluating the preliminary efficacy of aldoxorubicin in treating AIDS-related Kaposi’s sarcoma.
• December 2013 – As mentioned above, the company will release top-line progression-free survival results from the phase 2b 1st-Line Soft Tissue Sarcoma trial.
• 1st Quarter 2014 – CytRx will start a phase 3 pivotal trial with aldoxorubicin for 2nd-Line Soft Tissue Sarcoma in patients who have failed chemotherapy.
In conclusion, Equity Options Guru issues a positive take on the biopharmaceutical company, forecasting near-term growth based on its upcoming catalysts and financial standing.
“CytRx appears poised for significant growth over the next 6-12 months. The company is developing potential treatments in areas with a major unmet medical need. Should any of those treatments prove to be successful, it is likely that the share price could soar. With 4 major catalysts and a healthy financial position, investors may want to consider taking at least a small position in the company now before it’s too late,” wrote Equity Options Guru.
For more information on CytRx, visit www.cytrx.com
Please read full disclaimers at https://disclaimer.missionir.com